Prescription Drug Monitoring Program: Indiana State Profile (2021)

• NCJ Number: 303657
• Date Published: 2021
• Length: 12 pages
• Grant Number(s): 2017–AR–BX–K003
• Agencies: BJA-Sponsored
• Publication Type: Report (Grant Sponsored)

Annotation

The Prescription Drug Monitoring Program Training and Technical Assistance Center (PDMP TTAC) reports 2020 data and 2021 features of the Indiana state Prescription Drug Monitoring Program (PDMP).

 

Abstract

The acronym for the Indiana PDMP is INSPECT, and it is administered by the Indiana Professional Licensing Agency. The email address is provided, along with URLs for the PDMP website and related websites for enrollment and query. Contact information is provided for the Executive Director and the Director of INSPECT. For 2020, the Indiana state population was 6,790,280, and there were 34,786 DEA-registered prescribers and 1,252 DEA-registered dispensers. There are 16 types of reports available from INSPECT. Funding for INSPECT in 2021 is from controlled substance registration fees and unspecified “other” funding. Four staff members perform operational tasks, and two focus on technical issues. One employee performs tasks related to the analytical/epidemiological features of INSPECT’s work. The review of policies and procedures provides key dates in INSPECT’s development and information for accessing relevant state statutes and rules pertinent to INSPECT’s responsibilities and procedures. Miscellaneous capabilities and policies are also listed. Training is available for prescribers, dispensers, and law enforcement personnel. The features of PDMP accounts are listed. Law enforcement agencies’ use of the PDMP requires that the use be related to an active investigation. Access is through a web portal. Criteria for querying the PDMP are listed. Enrollment in the PDMP is required for prescribers and dispensers, and they are required to use the PDMP. Policies for veterinarians pertain to the monitoring of controlled drugs used with animals that will be accessible to their owners. Data monitored or accessible involves drugs on Schedules II-V, with the authority of the PDMP to monitor other substances. Data-processing technology capabilities are also reviewed.